AKT1 and pancreatic neoplasm: The application of the concept of synthetic lethality has initiated several studies combining inhibitors of PARP (olaparib) with PI3K inhibitor (BKM120) [60], testing PI3K-inhibitor LY294002 or AKT-inhibitor MK2206 in ARID1A mutated radio-resistant pancreatic cancer [71].